These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 31629930

  • 1. Macroporous organosilicon nanocomposites co-deliver Bcl2-converting peptide and chemotherapeutic agent for synergistic treatment against multidrug resistant cancer.
    Xie J, Xu W, Wu Y, Niu B, Zhang X.
    Cancer Lett; 2020 Jan 28; 469():340-354. PubMed ID: 31629930
    [Abstract] [Full Text] [Related]

  • 2. Unique Advantages of Dendrimers-Structured Mesoporous Silica Nanoparticles over Traditional Hollow Ones in Delivering Bcl2-Functional Converting Peptide for Multidrug Resistant Cancer Treatment.
    Wu Y, Ma F, Yu L, Lin R, Lin S, Guo Z, Zhou M, Li M, Zhang Y, Xie J.
    Adv Healthc Mater; 2024 Sep 28; 13(23):e2400888. PubMed ID: 38626918
    [Abstract] [Full Text] [Related]

  • 3. Macroporous silica nanoparticles for delivering Bcl2-function converting peptide to treat multidrug resistant-cancer cells.
    Xu W, Ge P, Niu B, Zhang X, Liu J, Xie J.
    J Colloid Interface Sci; 2018 Oct 01; 527():141-150. PubMed ID: 29787950
    [Abstract] [Full Text] [Related]

  • 4. Cancer-targeted and intracellular delivery of Bcl-2-converting peptide with functional macroporous silica nanoparticles for biosafe treatment.
    Wu Y, Ge P, Xu W, Li M, Kang Q, Zhang X, Xie J.
    Mater Sci Eng C Mater Biol Appl; 2020 Mar 01; 108():110386. PubMed ID: 31923940
    [Abstract] [Full Text] [Related]

  • 5. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
    Zhao P, Li L, Zhou S, Qiu L, Qian Z, Liu X, Cao X, Zhang H.
    Mater Sci Eng C Mater Biol Appl; 2018 Mar 01; 84():108-117. PubMed ID: 29519418
    [Abstract] [Full Text] [Related]

  • 6. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
    Guo XL, Kang XX, Wang YQ, Zhang XJ, Li CJ, Liu Y, Du LB.
    Acta Biomater; 2019 Jan 15; 84():367-377. PubMed ID: 30528609
    [Abstract] [Full Text] [Related]

  • 7. Acid-Responsive Macroporous Silica Nanoparticles for Bcl-2-Functional-Converting Peptide Release and Synergism with Celastrol for Enhanced Therapy against Resistant Cancer.
    Wu Y, Zhou M, Lin R, Yu L, Zhang X, Xie J.
    ACS Appl Mater Interfaces; 2023 Jun 28; 15(25):30427-30442. PubMed ID: 37312263
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Synthesis of New Antibacterial Cubane-based Nanocomposite and its Application in Combination Cancer Therapy.
    Zakerzadeh E, Salehi R, Mahkam M.
    Anticancer Agents Med Chem; 2018 Feb 07; 17(14):1898-1914. PubMed ID: 28530541
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.
    Cheng X, Li D, Sun M, He L, Zheng Y, Wang X, Tang R.
    Colloids Surf B Biointerfaces; 2019 Sep 01; 181():185-197. PubMed ID: 31132609
    [Abstract] [Full Text] [Related]

  • 14. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
    Tian F, Dahmani FZ, Qiao J, Ni J, Xiong H, Liu T, Zhou J, Yao J.
    Acta Biomater; 2018 Jul 15; 75():398-412. PubMed ID: 29874597
    [Abstract] [Full Text] [Related]

  • 15. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
    Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, Wu XY.
    Breast Cancer Res Treat; 2010 Jan 15; 119(2):255-69. PubMed ID: 19221875
    [Abstract] [Full Text] [Related]

  • 16. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
    Zhang X, Li F, Guo S, Chen X, Wang X, Li J, Gan Y.
    Biomaterials; 2014 Apr 15; 35(11):3650-65. PubMed ID: 24462359
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tumor-Specific Multiple Stimuli-Activated Dendrimeric Nanoassemblies with Metabolic Blockade Surmount Chemotherapy Resistance.
    Li Y, Xu X, Zhang X, Li Y, Zhang Z, Gu Z.
    ACS Nano; 2017 Jan 24; 11(1):416-429. PubMed ID: 28005335
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.